This is a working overview of purity testing, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-16. Anything still debated is marked as such rather than presented as settled.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Lt. Col. J. H. Fuller (18 April 1909 – 1 April 1911) Maj. Gordon Vallancy Drury (1 April 1911 – 28 January 1913) Maj. Gen. Sir Alfred Hamilton Mackenzie Edwards (28 January 1913 – 23 January 1923) Col. Algernon Essex Capell (1 February 1923 – 11 February 1926) Alfred James Tomlinson (12 February 1926 – 12 May 1926; acting) Col. George Stops (13 May 1926 – 14 February 1933) Brig. John Sidney Morris (15 February 1933 – 24 April 1945) Brig. John Ellis "Jack" Ross (24 April 1945 – 6 December 1950) Col. James Appleby (7 December 1950 – 2 June 1954) Col. Arthur Selwyn Hickman (3 June 1954 – 5 November 1955) Col. Harold Jackson (6 November 1955 – 12 March 1958) Basil Gordon Spurling (13 March 1958 – 25 April 1963) Frank Eric Barfoot (26 April 1963 – 2 January 1968) James Spink (3 January 1968 – 26 June 1970) Sydney Frederick Samuel Bristow (27 June 1970 – 6 February 1974) Peter Dennis Wray Richard Sherren (7 February 1974 – 6 February 1978) Peter Kevin Allum (7 February 1978 – 6 February 1982)
== Dextran nanoparticles == Dextran nanoparticles are 1-100 nm sized particles with drug encapsulation capability. The high surface area of these nanoparticles allows more drugs to be loaded and encapsulated, leading to higher drug concentrations at the target site. The small size of these particles also encourages cellular uptake, which makes dextran nanoparticles a potential effective drug delivery system for targeting tumor cells.
On 5 August 2024, Lula made a state visit to Chile where he separately met with president Gabriel Boric, Chile's Supreme Court chief justice Ricardo Blanco Herrera as well as Chile's Senate president José García Ruminot and House Speaker Karol Cariola. During the visit Lula and Boric signed a total of 19 treaties regarding tourism, space cooperation, mutual recognition for driver's licenses and extradition among other things. A group of 250 Brazilian business people accompanied Lula during the events.
Sources: en.wikipedia.org
Equine chorionic gonadotropin Gonadotropin preparations Human placental lactogen Pregnancy hormones Triple test, a screening test in pregnancy The Weight-Loss Cure "They" Don't Want You to Know About, a book written by Kevin Trudeau Chorionic+Gonadotropin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "History of pregnancy test". U.S. National Institutes of Health. Archived from the original on 2011-01-13. Retrieved 2011-01-10.
Matches in Team Fortress Classic typically feature two teams, one red and one blue, and nine playable character classes. Each character class has a set of weapons and abilities unique to that specific class. This differentiation between classes makes for rock-paper-scissors-esque gameplay that requires teammates to work together in order to effectively achieve the objective. The class-system also encourages players to vary their selection of classes and utilize certain classes in conjunction with one another to gain the advantage. In Team Fortress Classic, a server can hold up to 32 players simultaneously, and matches can be played in a number of game modes, each featuring different objectives.
=== Obstructive sleep apnea in pregnancy === Sleep apnea can result in intermittent hypoxia and has been increasing in prevalence due in part to the obesity epidemic. The known maternal risk factors for autism diagnosis in her offspring are similar to the risk factors for sleep apnea. For example, advanced maternal age, maternal obesity, maternal type 2 diabetes and maternal hypertension all increase the risk of autism in her offspring. Likewise, these are all known risk factors for sleep apnea. One study found that gestational sleep apnea was associated with low reading test scores in children and that this effect may be mediated by an increased risk of the child having sleep apnea themselves. Another study reported low social development scores in 64% of infants born to mothers with sleep apnea compared to 25% of infants born to controls, suggesting sleep apnea in pregnancy may have an effect on offspring neurodevelopment. There was also an increase in the amount of snoring the mothers with sleep apnea reported in their infants when compared to controls. Children with sleep apnea have "hyperactivity, attention problems, aggressivity, lower social competency, poorer communication, and/or diminished adaptive skills". One study found significant improvements in ADHD-like symptoms, aggression, social problems and thought problems in autistic children who underwent adenotonsillectomy for sleep apnea. Sleep problems in autism have been linked in a study to brain changes, particularly in the hippocampus, though this study does not prove causation.
Six reserve landing grounds were constructed for landing and take-off instruction to prevent congestion on the main airstrips. Later in the war, a dedicated air station was designated for the training of instructors. Small administrative units were established in South Africa at Cape Town, Durban and Port Elizabeth to handle incoming equipment and arrivals and departures of personnel. The complete pilot's course initially lasted six months, split into two months each of elementary, intermediate and advanced instruction. Ground subjects were also taught and each trainee had to fly at least 150 hours to qualify. By the end of the war each period had been shortened by a week to speed up the output of trained pilots. The trainees were mostly British, but came from all over the world. "The diversity of nationalities under training was surprising and impressive," reported one officer. "British, South African, New Zealand, Australian, Canadian, American, men from Yugoslavia, Greece, Free France, Poland, Czechoslovakia, Kenya, Uganda, Tanganyika, Fiji Isles, Malta." "[Southern Rhodesia's] part in the Commonwealth Air Training Scheme has been outstandingly fine," Sir James Ross of the British Air Ministry reported in 1942. "I say this from knowledge and without qualification. ... I know how gratefully the Air Staff in London reckon on the unfailingly regular flow of well-trained pilots and observers, course after course, month after month."
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.